As a cancer immunotherapy candidate, NILVs delivering the tumour antigen NY-ESO-1 to the human dendritic cells in vivo have shown promising clinical results by showing sustained CD8+ T cells within 14 days post-immunisation and anti-tumour responses [91,92]. This evidence concerns the gene CD8A and neoplasm.